DeLong Mark Jeffrey 4
4 · Apellis Pharmaceuticals, Inc. · Filed Jan 14, 2025
Insider Transaction Report
Form 4
DeLong Mark Jeffrey
Chief Business & Strat Officer
Transactions
- Sale
Common Stock
2025-01-13$28.70/sh−1,599$45,895→ 58,796 total
Footnotes (1)
- [F1]This represents shares sold to cover tax withholding on the Restricted Stock Units released on January 10, 2025.